100% Locally Owned, Independent and Free

100% Locally Owned, Independent and Free

Trial could be significant step forward in pursuit of new treatment for autoimmune disease

Do you have a news tip? Click here to send to our news team.

Childcare centre with 130 places proposed for development area

A new childcare centre is on the cards for a Sunshine Coast growth belt. Nirimba ELC Property One Pty Limited proposes to build a childcare More

Why airfares are rising: tourism expert

Multiple factors are contributing to elevated airfares this holiday season, according to a University of the Sunshine Coast tourism academic. Low competition, a shortage of More

Property experts join board of regional business group

Two property development experts have been appointed to the board of the region's leading business advocacy group. Stockland Aura project director Josh Sondergeld and Scanlon More

Sami Muirhead: rolling in festive bliss

What would your last meal be if you had to decide today? I know mine is a fresh prawn roll. Nothing in this world beats More

Photo of the day: after the storm

This photo was taken by Jo Allayialis from Cotton Tree pier after a storm. If you have a photo of the day offering, email photo@sunshinecoastnews.com.au More.

Coast’s highest rooftop bar and pool unveiled

The highest rooftop bar on the Sunshine Coast has opened, with its own pool and striking views of the beach and surrounding suburbs. The as-yet-unnamed More

A potential new treatment for rheumatoid arthritis will be tested on the Sunshine Coast.

The University of the Sunshine Coast Clinical Trials and Servatus Biopharmaceuticals Ltd are collaborating to trial a live biotherapeutic product, which is a field of medical therapy that is advancing globally.

Principal investigator Dr Peter de Wet said rheumatoid arthritis was an autoimmune disease that occurred when the immune system mistakenly attacked the body’s tissues, affecting the joints’ lining and causing joint pain and stiffness.

“Rheumatoid arthritis can be a debilitating condition that can impact many aspects of daily living,” he said via a UniSC media release.

“We are interested to learn about the role of the gut microbiome in treating symptoms of this condition.

“And while there are various strategies to improve joint mobility and muscle strength and reduce inflammation, some treatments are ineffective or have unwanted side effects, highlighting the need for new medicines to address the condition.”

He said the trial, to be held at UniSC’s newest clinic at Birtinya, represented a significant step forward in the pursuit of a new treatment.

Clinical Trials coordinator Jacinta Trevaskis.

Dr Samantha Coulson, head of clinical research at Servatus, said the live biotherapeutic product was an exciting and promising field of medical therapies that was advancing quickly on a global scale.

Servatus has isolated select microbial species, and pre-clinical investigations suggest the potential medication may be effective in treating autoimmune and inflammatory conditions.

“The gut microbiome plays such a vital role in many diseased states including rheumatoid arthritis, as the gut bacteria and immune system have a bidirectional influence on each other,” Dr Coulson said.

By using well-defined bacterial strains, we hope to regulate the hyperactive immune response seen in rheumatoid arthritis with significantly less side effects as with many of the current drugs in the market.

The product that could make a difference.

The team is seeking participants aged between 18 and 80 with confirmed rheumatoid arthritis and who are experiencing daily joint pain and stiffness.

Participants will need to commit to up to six visits at the Birtinya clinic over about four months and they will be reimbursed for their time on the trial.

Those interested in volunteering can find more information at UniSC Clinical Trials.

Local journalists supporting local people. Help keep independent and fair Sunshine Coast news coming by subscribing to our FREE daily news feed. All it requires is your name and email at the bottom of this article.

Subscribe to SCN’s free daily news email

Hidden
This field is for validation purposes and should be left unchanged.
[scn_go_back_button] Return Home
Share